TriangleT3011 (NCT06971614)
T3011 trial for Nonmuscle-invasive Bladder Cancer (NCT06971614). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with non-muscle-invasive bladder cancer unresponsive to BCG, or BCG-exposed and unresponsive to chemotherapy. Risk level and carcinoma-in-situ status determine the group.
The idea: T3011 is an engineered herpes virus designed to disrupt tumor cells and provide IL-12 and PD-1-blocking signals. Treatment goes into the bladder weekly for six weeks. Response assessment determines repeat induction or maintenance every three weeks. Researchers measure complete responses, recurrence, and safety. Prior muscle-invasive disease is excluded.
This phase 2 study plans 160 patients. ImmVira sponsors it; nine US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.